Swiss consensus on the role of DHEA in the management of genitourinary syndrome of menopause. (4th May 2022)

• Record Type: Journal Article
• Authors: Stute, P.; Bertschy, S.; Birkhaeuser, M.; Bitzer, J.; Ging, A.; Raggi, A.; Steimann, S.; Stute, V.
• Is Part Of: Climacteric. Volume 25:Number 3(2022)
• Page Start: 246
• Page End: 256
• Publication Date: 2022-05-04
• Subjects: Genitourinary syndrome of menopause -- prasterone -- vaginal estrogen -- personalized treatment -- drug facts box -- interdisciplinary consensus; Menopause -- Periodicals; Menopause -- Hormone therapy -- Periodicals; Menopause -- Periodicals; Estrogen Replacement Therapy -- Periodicals; Gynecology -- Periodicals; Societies, Medical -- Periodicals; 612.665
• DOI: 10.1080/13697137.2021.2008894
• Languages: English
• ISSNs: 1369-7137

Abstract

Abstract: Genitourinary syndrome of menopause (GSM) has a significantly negative impact on affected women's lives. However, despite the increasing number of GSM treatment options (e.g. non-hormonal vaginal products, vaginal hormones [estrogens], dehydroepiandrosterone [DHEA; prasterone], vaginal laser therapy, oral ospemifene), many women remain untreated. The goal of the Swiss interdisciplinary GSM consensus meeting was to develop tools for GSM management in daily practice: a GSM management algorithm (personalized medicine); a communication tool for vaginal DHEA (drug facts box); and a communication tool for understanding regulatory authorities and the discrepancy between scientific data and package inserts. The acceptance and applicability of such tools will be further investigated.